BCL2 and cancer: Navitoclax (ABT-263), a potent inhibitor of BCL-2, BCL-XL, and BCL-W, has demonstrated efficacy in eliminating a broad range of senescent cells, including therapy-induced senescent cancer cells (Czajkowski et al., 2025).